Premium
The current role of interferon in hairy cell leukaemia: clinical and molecular aspects
Author(s) -
Assanto Giovanni M.,
Riemma Costantino,
Malaspina Francesco,
Perrone Salvatore,
De Luca Maria L.,
Pucciarini Alessandra,
Annechini Giorgia,
D'Elia Gianna M.,
Martelli Maurizio,
Foà Robin,
Tiacci Enrico,
Pulsoni Alessandro
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17440
Subject(s) - medicine , purine analogue , retrospective cohort study , hairy cell leukemia , alpha interferon , interferon , gastroenterology , complete response , cohort , interferon α , refractory (planetary science) , oncology , immunology , chemotherapy , purine , leukemia , biology , biochemistry , astrobiology , enzyme
Summary We investigated the current role of interferon‐alpha (IFNα) in hairy cell leukaemia (HCL) in a retrospective analysis of patients with HCL. A cohort of 74 patients with HCL was divided in to three groups: (A) patients aged >65 years with first‐line treatment; (B) patients with comorbidities with first‐line treatment; (C) patients who were purine analogues resistant. In total, 94% achieved a response, with a complete response rate of 24%. After a median (range) follow‐up of 60 (7–236) months, 55 patients (78%) are still responding. The 5‐year progression‐free survival was 95%, 68%, and 96% in groups A, B and C respectively. A proportion of patients were monitored through their B‐Raf proto‐oncogene, serine/threonine kinase ( BRAF )‐V600E status. IFNα remains a possible option in select patients with HCL, where minimal residual disease negativity is achievable.